Key result
Fluphenazine decanoate induces reversible symptomatic bradycardia with heart rates down to ~46 bpm.
Why the study?
Bradycardia induced by fluphenazine decanoate has not been previously documented among the cardiovascular complications of antipsychotic agents.
Case Report (n=1)
No
May require cardiac monitoring with fluphenazine decanoate; leaves open whether this is a class effect.
Sinus tachycardia and orthostatic hypotension have been so far reported among the negative cardiovascular complications of antipsychotic agents. This study aimed to report a case with bradycardia induced by fluphenazine decanoate administration. The patient was a 29-year-old man, admitted to the general teaching hospital in Sari, Iran, with a complaint of abdominal and gastric pain as well as weight loss following 7 months of fasting based on religious delusions. The patient developed bradycardia, 36 hours after fluphenazine decanoate administration. His pulse rate was also 46 beats per min (bpm). The antipsychotic medication was thus held and the patient did not take any drugs. On the 21st day after discontinuing this agent, the pulse rate reached 70 bpm. This case report notifies that much more attention should be paid to all patients before starting fluphenazine decanoate administration, and close cardiac monitoring must be done.
No takes yet. Share an insight, caveat, or question.
Kamali et al. (2022) conducted a case report in Schizophrenia (n=1). Fluphenazine decanoate was evaluated on Development of bradycardia. Administration of fluphenazine decanoate induced symptomatic bradycardia with a pulse rate dropping to 46 beats per minute, which resolved following discontinuation of the medication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: